The FDA has approved Amgen and Allergan’s biosimilar of Roche’s Herceptin, just in time for the breast cancer blockbuster’s patent expiry. Herceptin’s main US patent expires this month ...

Mundipharma has signed a deal with Celltrion to market a biosimilar of Roche’s Herceptin (trastuzumab) in seven European countries. Breast cancer blockbuster Herceptin earned $2.26 billion in ...

Herceptin sales fell 11% to 1.38 billion Swiss francs ($1.5 billion) over the same period, while Perjeta’s 2024 sales dropped to 3.6 billion Swiss francs ($4 billion) versus roughly 3.8 billion ...

Research reports are not currently available for SMPC-R.BK.